1.      Branchford BR, Flood VH. Immune thrombocytopenic purpura (ITP). In: Kliegman RM, St. Geme JW, editors. Nelson Textbook of Pediatrics. 22nd ed. Philadelphia: Elsevier; 2023. p. 3049-3055.

2.      Cohen I, Goldvaser H, Kirgner I, Leader A, Raanani P, Isakov O, Shepshelovich D. Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Ann Hematol. 2021 Dec;100(12):2879-2887.

3.       Fan J, Chen J, Gao L, Tian Y, Sun Y, Yao Y, Zhan S, Hu S. Real-world experience of thrombopoietin receptor agonists in pediatric immune thrombocytopenia: a report from a Chinese tertiary children's hospital. Transl Pediatr. 2024 Jun 30;13(6):889-896.

4.      Gotesman M, Shear M, Raheel S, Procassini M, Panosyan EH. Pediatric immune thrombocytopenia. Adv Pediatr.2024;71(1):229–240.

5.       Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and PID. Blood.2022;140(6):542–555

6.      Graciaa S, Adeagbo S, Fong G, Rollins M, McElfresh P, Zerra PE, Bennett C, Josephson CD, Briones M, Fasano RM, Chonat S. Clinical features and neurological outcomes in pediatric immune-mediated thrombotic thrombocytopenic purpura: A report from a large pediatric hematology center. Pediatr Blood Cancer. 2022 Dec;69(12):e29992.

7.      Lanzkowsky P, Lipton JM, Fish JD, editors. Immune thrombocytopenic purpura (ITP). In: Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 6th ed. Philadelphia: Elsevier; 2016. p. 254–261.

8.      Maaloul I, Kolsi R, Chaari M, Ben Ameur S, Aloulou H, Kamoun T. Chronic immune thrombocytopenic purpura in children: Clinical presentations and management. Tunis Med. 2024 Nov 5;102(11):916-921. English.

9.      Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829–3866.

10.  Panch SR, Raman G, Bussel JB. Refractory ITP: revisiting definitions, diagnostics, and management paradigms. Hematology Am Soc Hematol Educ Program. 2025 Dec 5;2025(1):312-323.

11.  Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780–3817.

12.   Russo G, Parodi E, Farruggia P, Notarangelo LD, Perrotta S, Casale M, et al. Recommendations for the management of acute immune thrombocytopenia in children: a consensus conference from the Italian Association of Pediatric Hematology and Oncology. Blood Transfus. 2024; 22:253–265.

13.   Shimano KA, Grimes AB, Kaicker S, Shah SJ, Gunn E, Bhat RV, et al. Eltrombopag for newly diagnosed pediatric immune thrombocytopenia requiring treatment: the PINES randomized clinical trial. JAMA. 2025;334(20):1816–1826.

14.  Tumaini Massaro J, Chen Y, Ke Z. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis. Platelets. 2019;30(7):828-835.

15.  Türk Pediatrik Hematoloji Derneği. İmmün Trombositopeni Tanı ve Tedavi Kılavuzu. Ankara: Türk Pediatrik Hematoloji Derneği; 2020.